Core Viewpoint - Navient has released its financial results for the third quarter of 2025, indicating ongoing efforts to manage the cost of higher education for students and families [1]. Financial Results - The complete financial results for the third quarter of 2025 are available on Navient's investor website [1]. - A live audio webcast discussing these results will be hosted by the CEO and CFO on October 29, 2025, at 8 a.m. ET [1]. Company Overview - Navient focuses on helping students and families manage higher education costs through responsible lending, flexible refinancing, and trusted servicing [3]. - The company emphasizes creating long-term value for customers and investors, supported by decades of portfolio management expertise [3].

Core Insights - Gildan Activewear Inc. reported a strong third quarter for 2025, with net sales reaching $911 million, a 2.2% increase year-over-year, driven by a 5.4% growth in Activewear sales [3][7]. - The company achieved record adjusted diluted EPS of $1.00, reflecting a 17.6% increase from the previous year [9][21]. - Gildan's merger agreement with HanesBrands is expected to close by early 2026, which is anticipated to enhance its market position [16][17]. Financial Performance - Net sales for Q3 2025 were $911 million, with Activewear sales at $831 million, up 5.4% due to favorable product mix and higher prices [3][32]. - Gross profit for the quarter was $307 million, representing 33.7% of net sales, an improvement from 31.2% in the prior year [4][30]. - Operating income was $192 million, or 21.1% of net sales, slightly down from 21.7% in the previous year, but adjusted operating income increased to $212 million, or 23.2% of net sales [6][31]. Expense Management - SG&A expenses rose to $95 million, up from $84 million in the prior year, primarily due to higher variable compensation and IT-related expenses [5][12]. - Net financial expenses increased to $44 million, attributed to fees related to financing for the HanesBrands acquisition [8][14]. Year-to-Date Results - Year-to-date net sales reached $2,541 million, a 3.7% increase compared to the same period last year, with Activewear sales up 8.7% [10][11]. - Gross margin improved to 32.2%, up 150 basis points year-over-year, driven by lower raw material costs and favorable pricing [11][30]. - Adjusted diluted EPS for the year-to-date was $2.55, a 17% increase from the previous year [14][46]. Merger and Acquisition - The merger with HanesBrands is valued at approximately $2.2 billion in equity and $4.4 billion in enterprise value, with Gildan shareholders set to receive shares and cash for their HanesBrands stock [16][17]. - The transaction is expected to enhance Gildan's capabilities and market reach, aligning with its growth strategy [2][18]. 2025 Guidance Update - The company updated its full-year guidance, projecting revenue growth in the mid-single digits and adjusted diluted EPS in the range of $3.45 to $3.51, reflecting a 15% to 17% year-over-year increase [21][19]. - Free cash flow is expected to be approximately $400 million, down from previous guidance of above $450 million [21][19]. Dividend Declaration - The Board of Directors declared a cash dividend of $0.226 per share, payable on December 15, 2025, to shareholders of record as of November 19, 2025 [22]. ESG Recognition - Gildan was recognized as one of Canada's Best 50 Corporate Citizens for the fourth consecutive year and featured on TIME's World's Most Sustainable Companies list [20].

Core Insights - Chart Industries, Inc. reported a significant increase in orders and sales for the third quarter of 2025, with orders reaching $1.68 billion, a 43.9% increase compared to the same period in 2024 [4][7]. - The company is in the process of being acquired by Baker Hughes, with a definitive agreement for Baker Hughes to acquire all outstanding shares of Chart's common stock for $210 per share in cash [1][15]. - The company recorded a termination fee expense of $266 million related to a previously proposed merger with Flowserve, impacting reported operating income [1][34]. Financial Performance - Total sales for the third quarter of 2025 were $1.1 billion, reflecting a 3.6% increase year-over-year, with a notable increase of 9.7% when excluding the Repair, Service and Leasing segment [6][8]. - The adjusted operating income margin reached a record 22.9%, with gross profit as a percentage of sales remaining flat at 34.1% [7][8]. - Reported diluted earnings per share (EPS) were ($3.23), but adjusted EPS increased by 27.5% to $2.78 compared to the third quarter of 2024 [8]. Segment Performance - Cryo Tank Solutions (CTS) saw orders decrease by 8.0% to $116.1 million, with sales declining by 7.0% to $151.2 million due to lower industrial gas sales [9]. - Heat Transfer Systems (HTS) experienced a significant increase in orders, up 79.1% to $760.8 million, and sales increased by 36.3% to $349.3 million, driven by demand in LNG and data centers [10]. - Specialty Products orders grew by 84.4% to $438.5 million, although sales decreased by 4.7% to $269.9 million due to timing issues and non-repeat of higher sales from the previous year [11]. - The Repair, Service and Leasing segment saw orders decrease by 3.4% to $365.0 million, with sales declining by 8.4% to $330.2 million [12]. Balance Sheet and Cash Flow - The company reported net cash from operating activities of $118.0 million, resulting in free cash flow of $94.7 million after capital expenditures of $23.3 million [13]. - The net leverage ratio improved to 2.78, down from 2.85 in the previous quarter and 3.04 in the same quarter last year [13]. - Total assets increased to $9.79 billion as of September 30, 2025, compared to $9.12 billion at the end of 2024 [29]. Acquisition Details - The acquisition by Baker Hughes was approved by approximately 99% of Chart's shareholders on October 6, 2025, with the transaction expected to close by mid-2026 [15][16]. - The merger agreement stipulates that Chart shareholders will receive $210 per share in cash upon completion of the transaction [15].

Core Insights - Kyverna Therapeutics announced positive interim data from the Phase 2 portion of the KYSA-6 clinical trial for KYV-101 in generalized myasthenia gravis (gMG), achieving 100% clinically meaningful responses in primary endpoints [1][2][5] - The results indicate that KYV-101 can provide rapid and durable symptom improvement with a single dose, potentially leading to drug-free, disease-free remission [2][5][10] Efficacy - 100% of patients (6 out of 6) achieved clinically meaningful reductions in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores, with mean reductions of -8.0 points and -7.7 points at 24 weeks, respectively [6][12] - Deep responses were observed as early as two weeks post-treatment, indicating rapid efficacy [6][12] Safety - KYV-101 was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) reported [12] - One patient experienced a serious adverse event of Grade 4 neutropenia, which improved with standard supportive care [12] Clinical Trial Design - The Phase 2 portion of the KYSA-6 trial is a single-arm, open-label, multicenter study focusing on the efficacy and safety of KYV-101 in gMG [3][8] - The trial was amended to a registrational Phase 2/3 study following discussions with the FDA [8] Future Plans - The company plans to initiate enrollment for the Phase 3 portion of the trial by the end of the year and will share updated data from the Phase 2 portion next year [5][12] - Kyverna aims to establish a first-in-class neuroimmunology franchise and expand growth opportunities across multiple autoimmune indications [2][13]

Core Insights - NetraMark Holdings Inc. is leveraging its AI technology, NetraAI, to enhance clinical trials in the pharmaceutical industry, particularly for major depressive disorder (MDD) [1][10] Group 1: Presentation Highlights - At the ISCTM Autumn conference and ECNP Congress, NetraMark showcased two significant applications of its technology, focusing on ketamine and escitalopram trials [1][5] - The first presentation demonstrated how NetraAI identified distinct patient responder subgroups in ketamine trials, revealing that ketamine responders had unique baseline characteristics compared to placebo responders [2][3] - The second presentation introduced a novel algorithm that improved predictive accuracy in heterogeneous MDD trials, specifically for escitalopram response, by identifying a compact feature set related to anhedonia and mood [5][6] Group 2: Key Findings - In the ketamine trial, responder subgroups diverged significantly from placebo responders by the second infusion, indicating that ketamine's efficacy is not merely due to functional unblinding [4][8] - NetraAI's analysis in the CAN-BIND trial reduced clinical variables from 718 to 8 key variables, enhancing prediction accuracy and identifying a subgroup of highly predictive responders [9][7] - The technology revealed a genetic signature linked to neuroplasticity, allowing for a 91% accuracy in predicting treatment success when retrained on specific features [17] Group 3: Implications for Clinical Trials - NetraAI's capabilities can help overcome traditional barriers in CNS drug development by improving patient stratification, reducing placebo-related noise, and enhancing predictive modeling [10][12] - The advancements in distinguishing true pharmacologic effects from placebo responses represent a significant step forward in the design and interpretation of psychiatric and CNS trials [11][12] - As precision medicine becomes increasingly important, NetraMark's innovations provide a robust toolkit for pharmaceutical companies to uncover meaningful patient subgroups and accelerate drug development timelines [12][14]

Core Insights - Verizon Communications Inc. reported third-quarter 2025 results, indicating a positive trajectory towards achieving full-year financial guidance [1][9] - CEO Dan Schulman emphasized a shift to a customer-first culture and aggressive transformation of the company's operations and financial profile [2] Financial Performance - Earnings per share (EPS) for Q3 2025 was $1.17, up from $0.78 in Q3 2024; adjusted EPS was $1.21 compared to $1.19 in Q3 2024 [7][24] - Total operating revenue reached $33.8 billion, reflecting a year-over-year increase of 1.5% [7] - Consolidated net income for Q3 2025 was $5.1 billion, compared to $3.4 billion in Q3 2024 [7] - Cash flow from operating activities for the first nine months of 2025 was $28.0 billion, up from $26.5 billion in the same period of 2024 [7] - Free cash flow for the first nine months of 2025 was $15.8 billion, an increase from $14.5 billion in 2024 [7] Revenue Segments - Wireless service revenue grew to $21.0 billion in Q3 2025, marking a 2.1% increase year-over-year [7] - Verizon Consumer revenue totaled $26.1 billion in Q3 2025, up 2.9% year-over-year [7] - Total Verizon Business revenue was $7.1 billion in Q3 2025, a decrease of 2.8% year-over-year [11] Subscriber Metrics - Consumer wireless retail postpaid churn was 1.12% in Q3 2025, while wireless retail postpaid phone churn was 0.91% [11] - Verizon delivered 306,000 broadband net additions in Q3 2025, with total broadband connections exceeding 13.2 million, representing an 11.1% increase year-over-year [7][11] - Business reported 110,000 wireless retail postpaid net additions in Q3 2025, including 51,000 postpaid phone net additions [11] Debt and Financial Ratios - Total unsecured debt at the end of Q3 2025 was $119.7 billion, down from $126.4 billion at the end of Q3 2024 [7] - The ratio of unsecured debt to consolidated net income (LTM) was 5.9 times, and net unsecured debt to consolidated adjusted EBITDA ratio was 2.2 times [7][22] Outlook and Guidance - Verizon remains confident in its full-year guidance, expecting capital expenditures to be within or below the previously guided range of $17.5 billion to $18.5 billion [9][12] - The company anticipates total wireless service revenue growth of 2.0% to 2.8% and adjusted EBITDA growth of 2.5% to 3.5% for the full year [12]

Core Insights - Parsons Corporation has been awarded a $56 million contract for Phase 2 of the Diriyah project, which is a 5-year engagement aimed at enhancing urban development in Saudi Arabia [1][4] - The Diriyah project is part of Saudi Arabia's Vision 2030, focusing on creating a mixed-use urban destination that integrates traditional Najdi architecture with modern urban planning [3][10] Group 1: Contract Details - The contract involves the design and delivery of parks, open spaces, and over 55 kilometers of streetscape, including streets, footpaths, and civic buildings [2] - This contract represents new work for Parsons Corporation, which has been a partner in various urban development projects in Saudi Arabia since 2017 [4][5] Group 2: Project Significance - Diriyah is historically significant as the birthplace of Saudi Arabia and is home to the UNESCO World Heritage Site, At-Turaif [3][8] - The development aims to create a walkable city for approximately 100,000 residents and accommodate nearly 50 million visits annually [4][9] Group 3: Company Background - Parsons Corporation has over 65 years of experience in Saudi Arabia and currently manages more than 50 active projects, including mega and giga projects [5] - The company specializes in urban development, transport infrastructure, and sustainability, contributing to the Kingdom's economic diversification efforts [6][11]

Core Insights - Constellium SE reported strong financial results for Q3 2025, with significant increases in revenue, net income, and Adjusted EBITDA compared to Q3 2024 [5][6][21] - The company appointed Ingrid Joerg as the new CEO, effective January 1, 2026, succeeding Jean-Marc Germain, who will retire at the end of 2025 [3][5] - The company raised its guidance for 2025, expecting Adjusted EBITDA to be in the range of $670 million to $690 million and Free Cash Flow to exceed $120 million [3][27] Financial Performance - Q3 2025 shipments reached 373 thousand metric tons, a 6% increase from Q3 2024, with revenue of $2.2 billion, up 20% year-over-year [5][6] - Net income for Q3 2025 was $88 million, compared to $8 million in Q3 2024, while Adjusted EBITDA increased to $235 million, an 85% rise from the previous year [5][6][21] - For the first nine months of 2025, shipments totaled 1.1 million metric tons, up 2% from the same period in 2024, with revenue of $6.2 billion, an 11% increase [7][6] Segment Performance - Aerospace & Transportation (A&T) segment Adjusted EBITDA for Q3 2025 was $90 million, a 67% increase from Q3 2024, driven by higher shipments and favorable pricing [10][11] - Packaging & Automotive Rolled Products (P&ARP) segment Adjusted EBITDA rose to $82 million in Q3 2025, a 14% increase, supported by improved performance at Muscle Shoals [12][14] - Automotive Structures & Industry (AS&I) segment Adjusted EBITDA increased significantly to $33 million in Q3 2025, up 371% from the previous year, despite lower shipments [15][16] Cash Flow and Liquidity - Free Cash Flow for the first nine months of 2025 was $68 million, a significant improvement from $(15) million in the same period of 2024 [23] - Cash flows from operating activities were $271 million for the first nine months of 2025, compared to $240 million in the prior year [24] - As of September 30, 2025, the company had liquidity of $831 million, consisting of $122 million in cash and cash equivalents [26] Outlook and Strategic Developments - The company expects demand trends to remain stable through the end of 2025, benefiting from improved market dynamics [3][27] - Constellium completed the divestment of its Nanjing Automotive Structures plant in August 2025, indicating a strategic shift in operations [29]

COMPANY ANNOUNCEMENT NO. 36-2025 FLSmidth & Co. A/S 29 October 2025 Copenhagen, Denmark FLSmidth & Co. A/S (“FLSmidth” or the “Company”) hereby announces the following notification received pursuant to section 39 of the Danish Capital Markets Act from Société Générale S.A. regarding its holdings of financial instruments relating to shares in FLSmidth. On 28 October 2025, Société Générale S.A. informed FLSmidth that, as of 22 October 2025, its aggregate holding of financial instruments with a similar economi ...

PLANO, Texas, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Katapult Holdings, Inc. (NASDAQ: KPLT), an e-commerce-focused financial technology company, today announced it will release its third quarter 2025 financial results before the market opens on Wednesday, November 12, 2025. The company will host a conference call and webcast to discuss these results at 8:00 AM ET that same day. A live audio webcast of the conference call will be available on the Katapult Investor Relations website at http://ir.katapultholdings.c ...